tiprankstipranks

Biogen reports Q4 EPS $4.05, consensus $3.48

Reports Q4 revenue $2.54B, consensus $2.44B. Biogen President and CEO Christopher Viehbacher said: "Strategically, we are working to put Biogen on a sustainable growth trajectory as we execute on two important near-term opportunities with LEQEMBI in Alzheimer’s disease and zuranolone in depression, further diversify our product portfolio, and seek expansion through organic and external opportunities, including new partnerships. I believe we have a solid foundation on which to build Biogen’s future, including strong internal talent with a passion for making a difference for patients."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BIIB:

Disclaimer & DisclosureReport an Issue